$70.65
-1.93-2.66%
Last update: Oct 23, 6:55 PM
Monopar Therapeutics Inc (MNPR) Stock Price, Quote, News & History
MNPRNASDAQ
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.
You can purchase shares of Monopar Therapeutics (NASDAQ:MNPR) through any online brokerage.
Other companies in Monopar Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Monopar Therapeutics has a consensus price target of $97.53.
The stock price for Monopar Therapeutics (NASDAQ: MNPR) is $71.99 last updated October 23, 2026 at 6:55 PM EDT.
There are no upcoming dividends for Monopar Therapeutics.
Monopar Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Monopar Therapeutics.
Monopar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily,...
